echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Cancer Commun: Efficacy and toxicity of immune checkpoint inhibitors in the treatment of colorectal cancer: a real-world study

    Cancer Commun: Efficacy and toxicity of immune checkpoint inhibitors in the treatment of colorectal cancer: a real-world study

    • Last Update: 2021-08-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Colorectal cancer (CRC) is a common malignant tumor in China and the world


    Colorectal cancer (CRC) is a common malignant tumor in China and the world


    The study included 69 patients with CRC who received ICB treatment at Sun Yat-sen University Cancer Hospital from March 1, 2017 to October 1, 2019


    The study included 69 patients with CRC who received ICB treatment at Sun Yat-sen University Cancer Hospital from March 1, 2017 to October 1, 2019


    The median age at the beginning of ICB treatment was 45 years (range 16-67 years)


    Before immunotherapy, 55 cases (79.


    The median time from the initial diagnosis of CRC to the first ICB treatment was 6.


    As of January 4, 2021, all patients had a median follow-up of 15.




    Univariate analysis found that dMMR/MSI-H status and the use of early immunotherapy were significantly associated with good OS (P<0.




    65 patients reported treatment-related adverse events (TRAE)


    In summary, like clinical studies, ICB is more effective for dMMR/MSI-H compared to pMMR/MSI-L/MSS CRC patients


    Original source:

    Zhou C, Jiang T, Li R, et al.


    Zhou C, Jiang T, Li R, et al.
    Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis.
    Cancer Commun (Lond).
    2021 Jul 30.
    doi: 10.
    1002/cac2.
    12199.
    Epub ahead of print.
    PMID: 34327863.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.